Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 436572, 12 pages
http://dx.doi.org/10.1155/2015/436572
Review Article

Roles of Lymphocyte Kv1.3-Channels in the Pathogenesis of Renal Diseases and Novel Therapeutic Implications of Targeting the Channels

Department of Physiology I, Tohoku University Graduate School of Medicine, Seiryo-cho, Aoba-ku, Sendai, Miyagi 980-8575, Japan

Received 17 December 2014; Accepted 25 February 2015

Academic Editor: Augusto Vaglio

Copyright © 2015 Itsuro Kazama. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. D. Cahalan, K. G. Chandy, T. E. DeCoursey, and S. Gupta, “A voltage-gated potassium channel in human T lymphocytes,” Journal of Physiology, vol. 358, pp. 197–237, 1985. View at Publisher · View at Google Scholar · View at Scopus
  2. T. E. DeCoursey, K. G. Chandy, S. Gupta, and M. D. Cahalan, “Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis?” Nature, vol. 307, no. 5950, pp. 465–468, 1984. View at Publisher · View at Google Scholar · View at Scopus
  3. R. S. Lewis and M. D. Cahalan, “Potassium and calcium channels in lymphocytes,” Annual Review of Immunology, vol. 13, pp. 623–653, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. M. D. Cahalan, H. Wulff, and K. G. Chandy, “Molecular properties and physiological roles of ion channels in the immune system,” Journal of Clinical Immunology, vol. 21, no. 4, pp. 235–252, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Hu, M. Pennington, Q. Jiang, K. A. Whartenby, and P. A. Calabresi, “Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes,” Journal of Immunology, vol. 179, no. 7, pp. 4563–4570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Kazama, “Physiological significance of delayed rectifier K+ channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease,” The Journal of Physiological Sciences, vol. 65, no. 1, pp. 25–35, 2015. View at Publisher · View at Google Scholar
  7. K. Kumano, K. Kogure, T. Tanaka, and T. Sakai, “A new method of inducing experimental chronic renal failure by cryosurgery,” Kidney International, vol. 30, no. 3, pp. 433–436, 1986. View at Publisher · View at Google Scholar · View at Scopus
  8. S. E. Jones, D. J. Kelly, A. J. Cox, Y. Zhang, R. M. Gow, and R. E. Gilbert, “Mast cell infiltration and chemokine expression in progressive renal disease,” Kidney International, vol. 64, no. 3, pp. 906–913, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Hyodo, T. Oda, Y. Kikuchi et al., “Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis,” The American Journal of Physiology—Renal Physiology, vol. 299, no. 6, pp. F1258–F1269, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Grgic, H. Wulff, I. Eichler, C. Flothmann, R. Köhler, and J. Hoyer, “Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection,” Transplantation Proceedings, vol. 41, no. 6, pp. 2601–2606, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Kazama, Y. Maruyama, Y. Endo et al., “Overexpression of delayed rectifier K+ channels promotes in situ proliferation of leukocytes in rat kidneys with advanced chronic renal failure,” International Journal of Nephrology, vol. 2012, Article ID 581581, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Chatenoud, B. Dugas, G. Beaurain et al., “Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 19, pp. 7457–7461, 1986. View at Publisher · View at Google Scholar · View at Scopus
  13. G. A. Kaysen and V. Kumar, “Inflammation in ESRD: causes and potential consequences,” Journal of Renal Nutrition, vol. 13, no. 2, pp. 158–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. D. V. Barreto, F. C. Barreto, S. Liabeuf et al., “Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease,” Kidney International, vol. 77, no. 6, pp. 550–556, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. K. G. Chandy, H. Wulff, C. Beeton, M. Pennington, G. A. Gutman, and M. D. Cahalan, “K+ channels as targets for specific immunomodulation,” Trends in Pharmacological Sciences, vol. 25, no. 5, pp. 280–289, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Sugiyama, K. Isogai, A. Toyama et al., “Correlation between the pharmacological efficacy of cyclosporine and tacrolimus as evaluated by the lymphocyte immunosuppressant sensitivity test (LIST) and the MTT assay procedure in patients before and after renal transplantation,” International Journal of Clinical Pharmacology and Therapeutics, vol. 49, no. 2, pp. 145–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Rangaraju, V. Chi, M. W. Pennington, and K. G. Chandy, “Kv1.3 potassium channels as a therapeutic target in multiple sclerosis,” Expert Opinion on Therapeutic Targets, vol. 13, no. 8, pp. 909–924, 2009. View at Google Scholar · View at Scopus
  18. I. Kazama, Y. Maruyama, and M. Matsubara, “Benidipine persistently inhibits delayed rectifier K+-channel currents in murine thymocytes,” Immunopharmacology and Immunotoxicology, vol. 35, no. 1, pp. 28–33, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Baba, M. Tachi, Y. Maruyama, and I. Kazama, “Suppressive effects of diltiazem and verapamil on delayed rectifier K+-channel currents in murine thymocytes,” Pharmacological Reports, 2015. View at Publisher · View at Google Scholar
  20. I. Kazama and Y. Maruyama, “Differential effects of clarithromycin and azithromycin on delayed rectifier K+-channel currents in murine thymocytes,” Pharmaceutical Biology, vol. 51, no. 6, pp. 760–765, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Kazama, A. Baba, and Y. Maruyama, “HMG-CoA reductase inhibitors pravastatin, lovastatin and simvastatin suppress delayed rectifier K(+)-channel currents in murine thymocytes,” Pharmacological Reports, vol. 66, no. 4, pp. 712–717, 2014. View at Publisher · View at Google Scholar
  22. G. A. Heap and D. A. van Heel, “The genetics of chronic inflammatory diseases,” Human Molecular Genetics, vol. 18, no. 1, pp. R101–R106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. L. V. Avioli, S. Scott, S. W. Lee, and H. F. de Luca, “Intestinal calcium absorption: Nature of defect in chronic renal disease,” Science, vol. 166, no. 3909, pp. 1154–1156, 1969. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Grgic, E. Kiss, B. P. Kaistha et al., “Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 34, pp. 14518–14523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Platt, M. H. Roscoe, and F. W. Smith, “Experimental renal failure,” Clinical Science, vol. 11, no. 3, pp. 217–231, 1952. View at Google Scholar · View at Scopus
  26. A. B. Morrison, “Experimentally induced chronic renal insufficiency in the rat,” Laboratory Investigation, vol. 11, pp. 321–332, 1962. View at Google Scholar
  27. S. A. Bencosme, R. S. Stone, H. Latta, and S. C. Madden, “Acute tubular and glomerular lesions in rat kidneys after uranium,” Archives of Pathology, vol. 69, pp. 470–476, 1960. View at Google Scholar · View at Scopus
  28. S. Fukuda and J. D. Kopple, “Chronic uremia syndrome in dogs induced with uranyl nitrate,” Nephron, vol. 25, no. 3, pp. 139–143, 1980. View at Publisher · View at Google Scholar · View at Scopus
  29. M. E. M. Allison, C. B. Wilson, and C. W. Gottschalk, “Pathophysiology of experimental glomerulonephritis in rats,” The Journal of Clinical Investigation, vol. 53, no. 5, pp. 1402–1423, 1974. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Kondo, H. Shigematsu, and Y. Kobayashi, “Cellular aspects of rabbit Masugi nephritis. II. Progressive glomerular injuries with crescent formation,” Laboratory Investigation, vol. 27, no. 6, pp. 620–631, 1972. View at Google Scholar · View at Scopus
  31. M. Michimata, I. Kazama, K. Mizukami et al., “Urinary concentration defect and limited expression of sodium cotransporter, rBSC1, in a rat model of chronic renal failure,” Nephron, vol. 93, no. 2, pp. p34–p41, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Suzuki, R. Hatano, M. Michimata et al., “Residual urinary concentrating ability and AQP2 expression in a rat model for chronic renal failure,” Nephron Physiology, vol. 99, no. 1, pp. p16–p22, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Sanada, H. Toyama, Y. Ejima, and M. Matsubara, “Potential for erythropoietin synthesis in kidney of uraemic rat alters depending on severity of renal failure,” Nephrology, vol. 14, no. 8, pp. 735–742, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Kazama, A. Baba, M. Matsubara, Y. Endo, H. Toyama, and Y. Ejima, “Benidipine suppresses in situ proliferation of leukocytes and slows the progression of renal fibrosis in rat kidneys with advanced chronic renal failure,” Nephron Experimental Nephrology, vol. 128, no. 1-2, pp. 67–79, 2014. View at Publisher · View at Google Scholar
  35. L. Liu, P. Kou, Q. Zeng et al., “CD4+ T lymphocytes, especially Th2 cells, contribute to the progress of renal fibrosis,” The American Journal of Nephrology, vol. 36, no. 4, pp. 386–396, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. A. M. El Nahas, S. Anderson, and K. P. G. Harris, Eds., Mechanisms and Management of Progressive Renal Failure, Oxford University Press, London, UK, 2000.
  37. M. D. Cahalan and K. G. Chandy, “The functional network of ion channels in T lymphocytes,” Immunological Reviews, vol. 231, no. 1, pp. 59–87, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Kazama, Y. Maruyama, Y. Murata, and M. Sano, “Voltage-dependent biphasic effects of chloroquine on delayed rectifier K+-channel currents in murine thymocytes,” Journal of Physiological Sciences, vol. 62, no. 3, pp. 267–274, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Kazama, Y. Maruyama, and Y. Murata, “Suppressive effects of nonsteroidal anti-inflammatory drugs diclofenac sodium, salicylate and indomethacin on delayed rectifier K+-channel currents in murine thymocytes,” Immunopharmacology and Immunotoxicology, vol. 34, no. 5, pp. 874–878, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Ishida and T. M. Chused, “Lack of voltage sensitive potassium channels and generation of membrane potential by sodium potassium ATPase in murine T lymphocytes,” Journal of Immunology, vol. 151, no. 2, pp. 610–620, 1993. View at Google Scholar · View at Scopus
  41. C. Deutsch and L. Q. Chen, “Heterologous expression of specific K+ channels in T lymphocytes: functional consequences for volume regulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 21, pp. 10036–10040, 1993. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Teisseyre, S. C. Zmonarski, M. Klinger, J. W. Mozrzymas, and S. Miȩkisz, “Patch-clamp study on T-lymphocyte potassium conductance in patients with chronic renal failure,” Nephron, vol. 72, no. 4, pp. 587–594, 1996. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Abdul and N. Hoosein, “Expression and activity of potassium ion channels in human prostate cancer,” Cancer Letters, vol. 186, no. 1, pp. 99–105, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. S. H. Jang, K. S. Kang, P. D. Ryu, and S. Y. Lee, “Kv1.3 voltage-gated K+channel subunit as a potential diagnostic marker and therapeutic target for breast cancer,” BMB Reports, vol. 42, no. 8, pp. 535–539, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Huang, C.-T. Zhang, J.-R. Tang, L. Cai, Z. Zhang, and M.-G. Zhou, “Upregulated voltage-gated potassium channel Kv1.3 on CD4+CD28null T lymphocytes from patients with acute coronary syndrome,” Journal of Geriatric Cardiology, vol. 7, no. 1, pp. 40–46, 2010. View at Google Scholar · View at Scopus
  46. G. Toldi, A. Bajnok, D. Dobi et al., “The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis,” Immunobiology, vol. 218, no. 3, pp. 311–316, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Rus, C. A. Pardo, L. Hu et al., “The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 31, pp. 11094–11099, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Orbán, E. Biró, E. Grozdics, A. Bajnok, and G. Toldi, “Modulation of T lymphocyte calcium influx patterns via the inhibition of Kv1.3 and IKCa1 potassium channels in autoimmune disorders,” Frontiers in Immunology, vol. 4, article 234, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Han, H. Yi, S. J. Yin et al., “Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease,” The Journal of Biological Chemistry, vol. 283, no. 27, pp. 19058–19065, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Beeton, H. Wulff, J. Barbaria et al., “Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 24, pp. 13942–13947, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. W. F. Wonderlin and J. S. Strobl, “Potassium channels, proliferation and G1 progression,” Journal of Membrane Biology, vol. 154, no. 2, pp. 91–107, 1996. View at Publisher · View at Google Scholar · View at Scopus
  52. S. H. Jang, S. Y. Choi, P. D. Ryu, and S. Y. Lee, “Anti-proliferative effect of Kv1.3 blockers in A549 human lung adenocarcinoma in vitro and in vivo,” European Journal of Pharmacology, vol. 651, no. 1–3, pp. 26–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Ouadid-Ahidouch and A. Ahidouch, “K+ channel expression in human breast cancer cells: Involvement in cell cycle regulation and carcinogenesis,” Journal of Membrane Biology, vol. 221, no. 1, pp. 1–6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Braunwald, “Mechanism of action of calcium-channel-blocking agents,” The New England Journal of Medicine, vol. 307, no. 26, pp. 1618–1627, 1982. View at Publisher · View at Google Scholar · View at Scopus
  55. I. Palamaras and K. Kyriakos, “Calcium antagonists in dermatology: a review of the evidence and research-based studies,” Dermatology Online Journal, vol. 11, no. 2, 2005. View at Google Scholar · View at Scopus
  56. M. Horvath, Z. Mezey, A. Josfay, I. Nanay, M. Varsanyi, and S. Gero, “The effect of some drugs on in vitro cellular immune reactions and on circulating immune complexes in patients with myocardial infarction,” Journal of Investigational Allergology and Clinical Immunology, vol. 1, pp. 404–410, 1991. View at Google Scholar
  57. D. L. Birx, M. Berger, and T. A. Fleischer, “The interference of T cell activation by calcium channel blocking agents,” Journal of Immunology, vol. 133, no. 6, pp. 2904–2909, 1984. View at Google Scholar · View at Scopus
  58. K. B. Bacon, J. Westwick, and R. D. R. Camp, “Potent and specific inhibition of IL-8-, IL-1 alpha- and IL-1 beta-induced in vitro human lymphocyte migration by calcium channel antagonists,” Biochemical and Biophysical Research Communications, vol. 165, no. 1, pp. 349–354, 1989. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Matsumori, R. Nishio, and Y. Nose, “Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells,” Circulation Journal, vol. 74, no. 3, pp. 567–571, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. W. Liu and A. Matsumori, “Calcium channel blockers and modulation of innate immunity,” Current Opinion in Infectious Diseases, vol. 24, no. 3, pp. 254–258, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Furukawa, T. Yamakawa, T. Midera, T. Sagawa, Y. Mori, and T. Nukada, “Selectivities of dihydropyridine derivatives in blocking Ca2+ channel subtypes expressed in Xenopus oocytes,” Journal of Pharmacology and Experimental Therapeutics, vol. 291, no. 2, pp. 464–473, 1999. View at Google Scholar · View at Scopus
  62. L. G. Herbette, D. W. Chester, and D. G. Rhodes, “Structural analysis of drug molecules in biological membranes,” Biophysical Journal, vol. 49, no. 1, pp. 91–94, 1986. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Kitakaze, K. Node, T. Minamino, H. Asanuma, T. Kuzuya, and M. Hori, “A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs,” Journal of the American College of Cardiology, vol. 33, no. 1, pp. 242–249, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Yamamoto, Y. Gotoh, Y. Imaizumi, and M. Watanabe, “Mechanisms of long-lasting effects of benidipine on Ca current in guinea-pig ventricular cells,” British Journal of Pharmacology, vol. 100, no. 4, pp. 669–676, 1990. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Karasawa and K. Kubo, “Calcium antagonistic effects and the in vitro duration of actions of KW-3049, a new 1,4-dihydropyridine derivative, in isolated canine coronary arteries,” Japanese Journal of Pharmacology, vol. 47, no. 1, pp. 35–44, 1988. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Hayashi, K. Homma, S. Wakino et al., “T-type Ca channel blockade as a determinant of kidney protection,” Keio Journal of Medicine, vol. 59, no. 3, pp. 84–95, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. G. Remuzzi, “Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia),” The Lancet, vol. 349, no. 9069, pp. 1857–1863, 1996. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Hayashi, S. Wakino, K. Homma, N. Sugano, and T. Saruta, “Pathophysiological significance of T-type Ca2+ channels: Role of T-type Ca2+ channels in renal microcirculation,” Journal of Pharmacological Sciences, vol. 99, no. 3, pp. 221–227, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Nakamura, E. Sato, N. Fujiwara et al., “Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease,” The American Journal of the Medical Sciences, vol. 339, no. 2, pp. 157–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. U. Andersson, H. Wang, K. Palmblad et al., “High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes,” The Journal of Experimental Medicine, vol. 192, no. 4, pp. 565–570, 2000. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Sugiyama, R. Shirai, H. Mukae et al., “Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells,” Clinical and Experimental Immunology, vol. 147, no. 3, pp. 540–546, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. K. Morikawa, J. Zhang, M. Nonaka, and S. Morikawa, “Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production,” International Journal of Antimicrobial Agents, vol. 19, no. 1, pp. 53–59, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. A. A. Khan, T. R. Slifer, F. G. Araujo, and J. S. Remington, “Effect of clarithromycin and azithromycin on production of cytokines by human monocytes,” International Journal of Antimicrobial Agents, vol. 11, no. 2, pp. 121–132, 1999. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Bessler, H. Salman, M. Bergman, R. Straussberg, and M. Djaldetti, “In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells,” Clinical Immunology, vol. 117, no. 1, pp. 73–77, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. R. S. Rosenson, C. C. Tangney, and L. C. Casey, “Inhibition of proinflammatory cytokine production by pravastatin,” The Lancet, vol. 353, no. 9157, pp. 983–984, 1999. View at Google Scholar · View at Scopus
  76. N. Villalonga, M. David, J. Bielańska et al., “Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels,” Biochemical Pharmacology, vol. 80, no. 6, pp. 858–866, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. K. Kalman, M. W. Pennington, M. D. Lanigan et al., “Shk-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide,” The Journal of Biological Chemistry, vol. 273, no. 49, pp. 32697–32707, 1998. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Schmitz, A. Sankaranarayanan, P. Azam et al., “Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory t cells in autoimmune diseases,” Molecular Pharmacology, vol. 68, no. 5, pp. 1254–1270, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. D. L. Hamilton, C. Beall, S. Jeromson, C. Chevtzoff, D. J. Cuthbertson, and M. L. J. Ashford, “Kv1.3 inhibitors have differential effects on glucose uptake and AMPK activity in skeletal muscle cell lines and mouse ex vivo skeletal muscle,” The Journal of Physiological Sciences, vol. 64, no. 1, pp. 13–20, 2014. View at Publisher · View at Google Scholar
  80. L. Leanza, P. O'Reilly, A. Doyle et al., “Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines,” Current Pharmaceutical Design, vol. 20, no. 2, pp. 189–200, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. R. J. Lewis and M. L. Garcia, “Therapeutic potential of venom peptides,” Nature Reviews Drug Discovery, vol. 2, no. 10, pp. 790–802, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. S. I. V. Judge, J. M. Lee, C. T. Bever Jr., and P. M. Hoffman, “Voltage-gated potassium channels in multiple sclerosis: overview and new implications for treatment of central nervous system inflammation and degeneration,” Journal of Rehabilitation Research and Development, vol. 43, no. 1, pp. 111–122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. L. I. Escobar, J. C. Martínez-Téllez, M. Salas et al., “A voltage-gated K+ current in renal inner medullary collecting duct cells,” The American Journal of Physiology—Cell Physiology, vol. 286, no. 4, pp. C965–C974, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. R. Carrisoza-Gaytán, C. Salvador, L. M. Satlin et al., “Potassium secretion by voltage-gated potassium channel Kv1.3 in the rat kidney,” The American Journal of Physiology - Renal Physiology, vol. 299, no. 1, pp. F255–F264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. K. George Chandy, M. Cahalan, M. Pennington, R. S. Norton, H. Wulff, and G. A. Gutman, “Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants,” Toxicon, vol. 39, no. 9, pp. 1269–1276, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Mouhat, G. Teodorescu, D. Homerick et al., “Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain,” Molecular Pharmacology, vol. 69, no. 1, pp. 354–362, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. I. Kazama, Y. Maruyama, and A. Baba, “Amphipath-induced plasma membrane curvature controls microparticle formation from adipocytes: novel therapeutic implications for metabolic disorders,” Medical Hypotheses, vol. 82, no. 2, pp. 196–198, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. I. Kazama, N. Sasagawa, and T. Nakajima, “Complete remission of human parvovirus B19 associated symptoms by loxoprofen in patients with atopic predispositions,” Case Reports in Medicine, vol. 2012, Article ID 703281, 4 pages, 2012. View at Publisher · View at Google Scholar
  89. I. Kazama, T. Tamada, and T. Nakajima, “Resolution of migratory pulmonary infiltrates by moxifloxacin in a patient with dual infection of Mycoplasma pneumoniae and Bordetella pertussis,” Infezioni in Medicina, vol. 20, no. 4, pp. 288–292, 2012. View at Google Scholar · View at Scopus
  90. I. Kazama and T. Nakajima, “Dual infection of Mycoplasma pneumoniae and Chlamydophila pneumoniae in patients with atopic predispositions successfully treated by moxifloxacin,” Infezioni in Medicina, vol. 22, no. 1, pp. 41–46, 2014. View at Google Scholar · View at Scopus
  91. I. Kazama and T. Nakajima, “A case of fitz-hugh-curtis syndrome complicated by appendicitis conservatively treated with antibiotics,” Clinical Medicine Insights: Case Reports, vol. 6, pp. 35–40, 2013. View at Publisher · View at Google Scholar · View at Scopus